Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1705432

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1705432

Multi Cancer Early Detection Global Market Report 2025

PUBLISHED:
PAGES: 200 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 4490
PDF (Site License)
USD 6490
PDF (Enterprise License)
USD 8490

Add to Cart

Multi-cancer early detection involves identifying and diagnosing various cancer types in their early stages through the examination of biomarkers and other indicators present in bodily fluids or tissues. The objective is to detect cancerous conditions affecting multiple organs or tissues before symptoms appear, thereby facilitating prompt intervention and enhancing treatment effectiveness.

The primary categories of multi-cancer early detection include liquid biopsy, gene panels, laboratory-developed tests (LDT), and other methodologies. Liquid biopsy, for instance, is a non-invasive diagnostic procedure that identifies cancer-related biomarkers, such as circulating tumor cells (CTCs) or cell-free DNA (cfDNA), from bodily fluids such as blood or urine. These tests provide valuable information on cancer detection, progression, and response to treatment. They are utilized across hospitals, diagnostic facilities, and other medical settings for diagnosing various cancer types, including both solid tumors and hematological malignancies.

The multi cancer early detection market research report is one of a series of new reports from The Business Research Company that provides multi cancer early detection market statistics, including the multi cancer early detection industry global market size, regional shares, competitors with multi cancer early detection market share, detailed multi cancer early detection market segments, market trends, and opportunities, and any further data you may need to thrive in the multi cancer early detection industry. This multi cancer early detection market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multi cancer early detection market size has grown rapidly in recent years. It will grow from $1.45 billion in 2024 to $1.74 billion in 2025 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to increasing prevalence of cancer, government initiatives and funding, growing awareness about early cancer detection, expansion of healthcare infrastructure, rising adoption of personalized medicine, decreasing costs of genetic testing.

The multi cancer early detection market size is expected to see rapid growth in the next few years. It will grow to $3.49 billion in 2029 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to expansion of telemedicine and digital health, growing emphasis on preventive healthcare, increasing adoption of precision oncology, advances in biomarker discovery, surge in direct-to-consumer genetic testing. Major trends in the forecast period include increasing use of AI and machine learning, growing adoption of liquid biopsy techniques, integration of multi-omics approaches, expansion of at-home testing kits, rising focus on early-stage cancer detection, development of minimally invasive diagnostics.

The increasing adoption of personalized medicine is poised to drive the expansion of the multi-cancer early detection market in the future. Personalized medicine, which customizes healthcare interventions based on individual characteristics and genetic makeup, is gaining traction due to its ability to enhance treatment efficacy. This trend is fueled by advancements in genomics, the growing complexity of diseases, and supportive regulatory frameworks. Personalized medicine amplifies the effectiveness of multi-cancer early detection by tailoring screening and treatment approaches to individual genetic and biomarker profiles. For instance, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases, up from six in 2022, including seven cancer treatments and three for various other conditions, as reported by the Personalized Medicine Coalition. Hence, the increasing embrace of personalized medicine is fostering growth in the multi-cancer early detection market.

Major companies in the multi-cancer early detection market are innovating ctDNA-based liquid biopsy tests to improve sensitivity, specificity, and early detection rates, ultimately enhancing patient outcomes. These tests detect circulating tumor DNA in the bloodstream, offering a non-invasive method to track tumor dynamics, treatment response, and early recurrence or minimal residual disease. For example, in May 2023, Lucence, a US-based cancer diagnostics firm, unveiled LucenceINSIGHT, a pioneering multi-cancer early detection (MCED) blood test, at their US headquarters. This ctDNA-based liquid biopsy test enables screening for 10 common cancers using a single blood sample. With approximately 78% of global cancer deaths linked to types lacking routine screening protocols, this blood test offers improved convenience and accessibility for asymptomatic individuals seeking screening for various cancer types.

In May 2023, Freenome Holdings Inc., a US-based biotechnology company, acquired Oncimmune Ltd. for an undisclosed sum. This acquisition is aimed at enhancing Freenome's early cancer detection capabilities by incorporating Oncimmune's autoantibody platform and expanding its multiomics portfolio. Oncimmune Ltd., a UK-based biotechnology firm, specializes in immunodiagnostics for cancer detection.

Major companies operating in the multi cancer early detection market are Illumina Inc., Sysmex Inostics GmbH, Exact Sciences Corporation, Natera Inc, Guardant Health, Core Diagnostics, Genecast Biotechnology Co. Ltd, Burning Rock Biotech Limited, Freenome Holdings Inc., Guangzhou AnchorDx Medical Co. Ltd, Singlera Genomics Incorporated, Naveris Inc. , Lucence Health Inc., PredOmix Technologies, Micronoma INC., EarlyDiagnostics (EarlyDx), Elypta AB, Predictive Oncology, ANPAC Bio-Medical Science Co. Ltd, CanSense Ltd, Epigenomics AG, VolitionRX, OncoSeek, Laboratory for Advanced Medicine, Inc., AnchorDx

North America was the largest region in the multi cancer early detection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multi cancer early detection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multi cancer early detection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multi-cancer early detection market consists of revenues earned by entities by providing services such as diagnostic imaging, screening tests, molecular diagnostics, and risk assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The multi-cancer early detection market also includes sales of assay panels, diagnostic kits, reagents, instruments, software solutions for data analysis and interpretation, and quality control materials. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multi Cancer Early Detection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multi cancer early detection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multi cancer early detection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multi cancer early detection market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Liquid Biopsy; Gene Panel; Laboratory Developed Tests (LDT); Other Types
  • 2) By Cancer Type: Solid Tumors; Hematological Malignancies
  • 3) By End-User: Hospitals; Diagnostic Laboratories; Other End Users
  • Subsegments:
  • 1) By Liquid Biopsy Types: Circulating Tumor Cells (CTC); Circulating Tumor DNA (Ctdna); Exosomes
  • 2) By Gene Panel: DNA-Based Panels; RNA-Based Panels; Multi-Gene Panels
  • 3) By Laboratory Developed Tests (LDT): PCR-Based Tests; Next-Generation Sequencing (NGS) Tests; Immunohistochemistry (IHC) Tests
  • 4) By Other Types: Protein Biomarkers; Autoantibody-Based Tests
  • Companies Mentioned: Illumina Inc.; Sysmex Inostics GmbH; Exact Sciences Corporation; Natera Inc; Guardant Health
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.
Product Code: r30742

Table of Contents

1. Executive Summary

2. Multi Cancer Early Detection Market Characteristics

3. Multi Cancer Early Detection Market Trends And Strategies

4. Multi Cancer Early Detection Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Multi Cancer Early Detection Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Multi Cancer Early Detection PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Multi Cancer Early Detection Market Growth Rate Analysis
  • 5.4. Global Multi Cancer Early Detection Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Multi Cancer Early Detection Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Multi Cancer Early Detection Total Addressable Market (TAM)

6. Multi Cancer Early Detection Market Segmentation

  • 6.1. Global Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Liquid Biopsy
  • Gene Panel
  • Laboratory Developed Tests (LDT)
  • Other Types
  • 6.2. Global Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Solid Tumors
  • Hematological Malignancies
  • 6.3. Global Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Diagnostic Laboratories
  • Other End Users
  • 6.4. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Liquid Biopsy Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Circulating Tumor Cells (CTC)
  • Circulating Tumor DNA (Ctdna)
  • Exosomes
  • 6.5. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Gene Panel, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • DNA-Based Panels
  • RNA-Based Panels
  • Multi-Gene Panels
  • 6.6. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Laboratory Developed Tests (LDT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PCR-Based Tests
  • Next-Generation Sequencing (NGS) Tests
  • Immunohistochemistry (IHC) Tests
  • 6.7. Global Multi Cancer Early Detection Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Protein Biomarkers
  • Autoantibody-Based Tests

7. Multi Cancer Early Detection Market Regional And Country Analysis

  • 7.1. Global Multi Cancer Early Detection Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Multi Cancer Early Detection Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Multi Cancer Early Detection Market

  • 8.1. Asia-Pacific Multi Cancer Early Detection Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Multi Cancer Early Detection Market

  • 9.1. China Multi Cancer Early Detection Market Overview
  • 9.2. China Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Multi Cancer Early Detection Market

  • 10.1. India Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Multi Cancer Early Detection Market

  • 11.1. Japan Multi Cancer Early Detection Market Overview
  • 11.2. Japan Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Multi Cancer Early Detection Market

  • 12.1. Australia Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Multi Cancer Early Detection Market

  • 13.1. Indonesia Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Multi Cancer Early Detection Market

  • 14.1. South Korea Multi Cancer Early Detection Market Overview
  • 14.2. South Korea Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Multi Cancer Early Detection Market

  • 15.1. Western Europe Multi Cancer Early Detection Market Overview
  • 15.2. Western Europe Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Multi Cancer Early Detection Market

  • 16.1. UK Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Multi Cancer Early Detection Market

  • 17.1. Germany Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Multi Cancer Early Detection Market

  • 18.1. France Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Multi Cancer Early Detection Market

  • 19.1. Italy Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Multi Cancer Early Detection Market

  • 20.1. Spain Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Multi Cancer Early Detection Market

  • 21.1. Eastern Europe Multi Cancer Early Detection Market Overview
  • 21.2. Eastern Europe Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Multi Cancer Early Detection Market

  • 22.1. Russia Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Multi Cancer Early Detection Market

  • 23.1. North America Multi Cancer Early Detection Market Overview
  • 23.2. North America Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Multi Cancer Early Detection Market

  • 24.1. USA Multi Cancer Early Detection Market Overview
  • 24.2. USA Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Multi Cancer Early Detection Market

  • 25.1. Canada Multi Cancer Early Detection Market Overview
  • 25.2. Canada Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Multi Cancer Early Detection Market

  • 26.1. South America Multi Cancer Early Detection Market Overview
  • 26.2. South America Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Multi Cancer Early Detection Market

  • 27.1. Brazil Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Multi Cancer Early Detection Market

  • 28.1. Middle East Multi Cancer Early Detection Market Overview
  • 28.2. Middle East Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Multi Cancer Early Detection Market

  • 29.1. Africa Multi Cancer Early Detection Market Overview
  • 29.2. Africa Multi Cancer Early Detection Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Multi Cancer Early Detection Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Multi Cancer Early Detection Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Multi Cancer Early Detection Market Competitive Landscape And Company Profiles

  • 30.1. Multi Cancer Early Detection Market Competitive Landscape
  • 30.2. Multi Cancer Early Detection Market Company Profiles
    • 30.2.1. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Sysmex Inostics GmbH Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Exact Sciences Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Natera Inc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Guardant Health Overview, Products and Services, Strategy and Financial Analysis

31. Multi Cancer Early Detection Market Other Major And Innovative Companies

  • 31.1. Core Diagnostics
  • 31.2. Genecast Biotechnology Co. Ltd
  • 31.3. Burning Rock Biotech Limited
  • 31.4. Freenome Holdings Inc.
  • 31.5. Guangzhou AnchorDx Medical Co. Ltd
  • 31.6. Singlera Genomics Incorporated
  • 31.7. Naveris Inc.
  • 31.8. Lucence Health Inc.
  • 31.9. PredOmix Technologies
  • 31.10. Micronoma INC.
  • 31.11. EarlyDiagnostics (EarlyDx)
  • 31.12. Elypta AB
  • 31.13. Predictive Oncology
  • 31.14. ANPAC Bio-Medical Science Co. Ltd
  • 31.15. CanSense Ltd

32. Global Multi Cancer Early Detection Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multi Cancer Early Detection Market

34. Recent Developments In The Multi Cancer Early Detection Market

35. Multi Cancer Early Detection Market High Potential Countries, Segments and Strategies

  • 35.1 Multi Cancer Early Detection Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Multi Cancer Early Detection Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Multi Cancer Early Detection Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!